Why is big Pharma getting out of antibacterial drug discovery?
Top Cited Papers
- 1 October 2003
- journal article
- review article
- Published by Elsevier in Current Opinion in Microbiology
- Vol. 6 (5), 427-430
- https://doi.org/10.1016/j.mib.2003.08.003
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Inhalational Anthrax Outbreak among Postal Workers, Washington, D.C., 2001Emerging Infectious Diseases, 2002
- Colistin: An Antimicrobial for the 21st Century?Clinical Infectious Diseases, 2002
- New (and not so new) antibacterial targets – from where and when will the novel drugs come?Current Opinion in Pharmacology, 2002
- N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial ActivityAntimicrobial Agents and Chemotherapy, 2002
- Putting a price on biotechnologyNature Biotechnology, 2001
- Antimicrobial Safety and Tolerability: Differences and DilemmasClinical Infectious Diseases, 2001
- Infectious Diseases: Considerations for the 21st CenturyClinical Infectious Diseases, 2001
- Clinical Characteristics and Molecular Epidemiology Associated with Imipenem‐Resistant Klebsiella pneumoniaeClinical Infectious Diseases, 1999